PPP2CB

Across TCGA pan-cancer cohorts, PPP2CB Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PPP2CB data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher PPP2CB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PPP2CB expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRC, CESC, and UCEC are the cancer types where PPP2CB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.141	0.655	.026	12	view →
CESC	OS	Median	All	0.013	0.875	<.001	12	view →
UCEC	OS	Median	All	1.000	0.652	.018	8	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PPP2CB–KIRC (OS)

Open the KIRC breakdown →